Key Insider Commits 6.4% Stake to Gilead Acquisition of Arcellx
ACLX has more than doubled off its 52-week low of $47.86 on elevated volume (10× avg).
Summary
Rami Elghandour, a significant insider, has filed an amended Schedule 13D confirming his agreement to tender his 6.4% beneficial ownership stake in Arcellx, Inc. as part of the acquisition by Gilead Sciences.
Key Events · M&A and Partnerships · ACLX
-
Insider Commits to Merger
Rami Elghandour, a significant insider, has agreed to tender his 3,938,771 shares (6.4% beneficial ownership) in the acquisition of Arcellx by Gilead Sciences.
-
Reinforces Deal Certainty
This commitment from a major shareholder and insider provides strong support for the $7.8 billion acquisition, which was announced on February 23, 2026.
-
Acquisition Terms Confirmed
The merger consideration includes $115.00 per share in cash plus a $5.00 Contingent Value Right (CVR).
Analysis · ACLX · Life Sciences
This Schedule 13D/A from Rami Elghandour provides crucial detail regarding insider support for the recently announced acquisition of Arcellx by Gilead Sciences. Elghandour, who beneficially owns 6.4% of Arcellx's common stock, has formally agreed to tender his shares in the $7.8 billion acquisition. This commitment from a major insider reinforces the certainty of the merger, which offers shareholders $115.00 per share in cash plus a $5.00 CVR. This filing follows the initial merger announcement on February 23, 2026, and signals strong internal alignment with the deal.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACLX was trading at $113.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $47.86 to $114.26. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.